HeartBeam has announced a partnership with electrocardiogram (ECG)-based diagnostics software company AccurKardia, aimed at improving cardiac monitoring solutions鈥� accessibility.
The alliance will focus on integrating AccurKardia’s ECG analysis software, AccurECG, with HeartBeam’s devices.
HeartBeam’s cable-free, credit card-sized ECG device is designed to capture the electrical signals of the heart in three non-coplanar directions.
It synthesises them into a 12-lead ECG with the help of a personalised transformation matrix.
HeartBeam noted that it is preparing to begin commercialisation following the US Food and Drug Administration鈥檚 (FDA) clearance for the ECG synthesis software.
The addition of AccurKardia’s device-agnostic automated ECG interpretation platform to HeartBeam’s device is expected to improve the forthcoming commercial offering for arrhythmia evaluation.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt will allow both the physicians and their patients to receive an automated rhythm evaluation, potentially leading to rapid diagnosis and accessibility to necessary clinical care.
HeartBeam CEO Robert Eno said: 鈥淭his collaboration is a major step forward in delivering a more accessible and scalable solution for remote cardiac monitoring.
鈥淎ccurKardia shares our mission of improving cardiac outcomes through technological innovation, and together we can accelerate the delivery of unprecedented cardiac insights to individuals and physicians outside of a medical facility.鈥�
The partnership is anticipated to accelerate the product development of HeartBeam, minimising the expenses and time to market.
AccurKardia CEO and co-founder Juan Jimenez said: 鈥淏y uniting our strengths, we鈥檙e creating a best鈥慽n鈥慶lass platform that transforms how cardiac arrhythmia conditions are monitored and detected.
鈥淧utting clinical-grade ECG insights directly into a patient鈥檚 pocket aims to meaningfully address the increasing lack of access to cardiology specialists in the US.鈥�
Cleared by the FDA, AccurECG is a Class II software as a medical device designed for real-time ECG interpretation.
In March 2024, HeartBeam obtained two new patents from the US Patent and Trademark Office for its core vector electrocardiography (VECG) technology.
